Everything below concerns BPC-157. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
FIAU is then phosphorylated stepwise: thymidine kinase (TK) converts FIAU to FIAU-monophosphate (FIAU-MP), then thymidylate kinase (TMPK) forms FIAU-diphosphate (FIAU-DP) and finally nucleoside-diphosphate kinase (DPK) produces FIAU-triphosphate (FIAU-TP). FIAU-TP can be incorporated into viral or cellular DNA (figure 4). In addition, thymidylate synthase (TS) has the potential to de-iodinate FIAU to FAU and then subsequently methylate FAU to FMAU monophosphate. FMAU monophosphate can subsequently be converted into FMAU diphosphate by thymidine monophosphate kinase (TMPK). Finally, FMAU diphosphate can be converted into FMAU triphosphate by the enzyme diphosphate kinase (DPK) with the purpose of incorporation into the viral or cellular DNA. FIAU does not exist as only one compound inside the cell, its metabolites can also contribute and FAU can ultimately be incorporated as FMAU in whole cells.
The process of selecting appropriate deep final repositories for high-level waste and spent fuel is now underway in several countries with the first expected to be commissioned sometime after 2010. The basic concept is to locate a large, stable geologic formation and use mining technology to excavate a tunnel, or use large-bore tunnel boring machines (similar to those used to drill the Channel Tunnel from England to France) to drill a shaft 500 to 1,000 metres (1,600 to 3,300 ft) below the surface where rooms or vaults can be excavated for disposal of high-level radioactive waste. The goal is to permanently isolate nuclear waste from the human environment. Many people remain uncomfortable with the immediate stewardship cessation of this disposal system, suggesting perpetual management and monitoring would be more prudent. Because some radioactive species have half-lives longer than one million years, even very low container leakage and radionuclide migration rates must be taken into account. Moreover, it may require more than one half-life until some nuclear materials lose enough radioactivity to cease being lethal to living things. A 1983 review of the Swedish radioactive waste disposal program by the National Academy of Sciences found that country's estimate of several hundred thousand years—perhaps up to one million years—being necessary for waste isolation "fully justified." The proposed land-based subductive waste disposal method disposes of nuclear waste in a subduction zone accessed from land and therefore is not prohibited by international agreement.
GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Unlike GLP-1 mono-agonists, which target only the GLP-1 receptor, poly-agonists activate two or more incretin receptors, such as the gastric inhibitory polypeptide (GIP) receptor, which have distinct features but work together in metabolic regulation. GIP and GLP-1 are both naturally released from the gastrointestinal tract after eating, but act on different receptor distributions across tissues. GLP-1 receptors are concentrated in the pancreas, brain, and gastrointestinal tract, while GIP receptors are found primarily in the pancreas, brain, and adipose tissue. In healthy people, the combined incretin effect of GIP and GLP-1 accounts for around 50–70% of post-meal insulin secretion. This effect is substantially reduced in people with type 2 diabetes, providing evidence for therapies that activate both hormones. Poly-agonists are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.
Sources: en.wikipedia.org
== Further reading == Robinson, David A. (2008), "Field Estimation of Soil Water Content: A Practical Guide to Methods, Instrumentation and Sensor Technology" (PDF), Soil Science Society of America Journal, 73 (4), Vienna, Austria: International Atomic Energy Agency: 131, Bibcode:2009SSASJ..73.1437R, doi:10.2136/sssaj2008.0016br, ISSN 1018-5518, IAEA-TCS-30 Wessel-Bothe, Weihermüller (2020): Field Measurement Methods in Soil Science. New practical guide to soil measurements explains the principles of operation of different moisture sensor types (independent of manufacturer), their accuracy, fields of application and how such sensors are installed, as well as subtleties of the data so obtained. Also deals with other crop-related soil parameters.
Analysis of clinical trial results that includes all data from participants in the groups to which they were randomized even if they never received the treatment. (NLM) The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given. It has the consequence that subjects allocated to a treatment group should be followed up, assessed and analysed as members of that group irrespective of their compliance to the planned course of treatment. (ICH E9) Interaction (Qualitative & Quantitative)
=== Australia === Joseph Banks and Daniel Solander, accompanying James Cook's first global circumnavigation, discovered in April 1770, in Botany Bay, two growing species of wild perennial soybeans (Glycine tabacina and Glycine tomentosa), and in June had found more in the future Queensland at Bustard Bay, Shoalwater Bay, and Endeavour River. In 1804, the first soyfood product ("Fine India Soy" [sauce]) was sold in Sydney. In 1879, the first domesticated soybeans arrived in Australia, a gift of the Minister of the Interior Department, Japan and were distributed to famers. The first recorded experiments in cultivation of soybeans in came after 1890.
Trent Reznor of Nine Inch Nails said in the 2010 documentary Rush: Beyond the Lighted Stage that Rush is one of his favourite bands, and he has also cited the band's early 1980s period in particular as a major influence on him in regard to incorporating keyboards and synthesizers into hard rock. Rush had been eligible for nomination into the Rock and Roll Hall of Fame since 1998. The band was nominated for entry in 2012, and their induction was announced on December 11, 2012. A reason for their previous exclusion may have been their genre. USA Today writer Edna Gundersen criticized the Hall of Fame for excluding some genres, including progressive rock. Supporters cited the band's accomplishments, including longevity, proficiency, and influence, as well as commercial sales figures and RIAA certifications. In the years before induction, Lifeson expressed his indifference toward the perceived slight, saying, "I couldn't care less. Look who's up for induction; it's a joke". In his acceptance speech on the occasion of Rush's induction into the Roll Hall of Fame on April 18, 2013, Lifeson spontaneously recited his prepared text in "blah blah blah" speech, annoying his band fellows and confusing the audience. On April 24, 2010, the documentary Rush: Beyond the Lighted Stage, directed by Scot McFadyen and Sam Dunn, premiered at the Tribeca Film Festival. It received the Tribeca Film Festival Audience Award. The film was nominated for Best Long Form Music Video at the 53rd Grammy Awards, losing to When You're Strange, a documentary about The Doors.
Sources: en.wikipedia.org
The UCIL factory was built in 1969 to produce the pesticide Sevin (UCC's brand name for carbaryl) using methyl isocyanate (MIC) as an intermediate. An MIC production plant was added to the UCIL site in 1979. The chemical process employed in the Bhopal plant had methylamine reacting with phosgene to form MIC, which was in turn reacted with 1-naphthol to form the final product, carbaryl. Another manufacturer, Bayer, also used this MIC-intermediate process at the chemical plant once owned by UCC at Institute, West Virginia in the United States. After the Bhopal plant was built, other manufacturers (including Bayer) produced carbaryl without MIC, though at a greater manufacturing cost. UCIL's process differed from the MIC-free routes used elsewhere, in which the same raw materials were combined in a different manufacturing order, with phosgene initially reacting with 1-naphthol to form a chloroformate ester, which was later reacted with methylamine. In the early 1980s, although the demand for pesticides had fallen, production continued leading to an accumulation of unused MIC at the Bhopal site.
=== Neurodegenerative disorders === Huntington disease. No reliable conclusion could be drawn regarding the effectiveness of THC or oral cannabis extract in treating the symptoms of Huntington disease as the available trials were too small to reliably detect any difference Parkinson's disease. Based on a single study, oral CBD extract was rated probably ineffective in treating levodopa-induced dyskinesia in Parkinson's disease. Alzheimer's disease. A 2009 Cochrane Review found insufficient evidence to conclude whether cannabis products have any utility in the treatment of Alzheimer's disease.
Particle-induced X-ray emission or proton-induced X-ray emission (PIXE) is a technique used for determining the elemental composition of a material or a sample. When a material is exposed to an ion beam, atomic interactions occur that give off EM radiation of wavelengths in the X-ray part of the electromagnetic spectrum specific to an element. PIXE is a powerful, yet non-destructive elemental analysis technique now used routinely by geologists, archaeologists, art conservators and others to help answer questions of provenance, dating and authenticity. The technique was first proposed in 1970 by Sven Johansson of Lund University, Sweden, and developed over the next few years with his colleagues Roland Akselsson and Thomas B Johansson. Recent extensions of PIXE using tightly focused beams (down to 1 μm) gives the additional capability of microscopic analysis. This technique, called microPIXE, can be used to determine the distribution of trace elements in a wide range of samples. A related technique, particle-induced gamma-ray emission (PIGE) can be used to detect some light elements. Additionally, there is a multiplexed instrument combining PIXE with mass spectrometry of molecules: PDI-PIXE-MS or PIXE-MS.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.